Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, recovered tumor immune surveillance by tumor-specific CTLs and achieved 12–28% overall response rates, resulting in the improvement of survival in refractory cancer patients with melanoma, renal cell carcinoma and non-small cell lung cancer [24,25]. Here, CD274 is linked to cancer.